Overview

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis

Status:
NOT_YET_RECRUITING

Trial end date:
2028-02-04

Target enrollment:

Participant gender:

Summary

This is a study to demonstrate the long-term safety, tolerability and clinical efficacy of sonelokimab in the treatment of patients with psoriatic arthritis who completed a parental study (M1095-PSA-301 or M1095-PSA-302)

Phase:

PHASE3

Details

Lead Sponsor:

MoonLake Immunotherapeutics AG

Treatments:

sonelokimab